

10-28-04

IFW

PATENT
ATTORNEY DOCKET NO. 10498-00059

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
Donald M. Coen and Beatrice D. Pilger)	Examiner:
)	
Serial No.: 10/712,785)	
)	
Filed: November 13, 2003)	Art Unit: 2812
)	
Title: METHOD FOR DETERMINING PROTEIN)	
INTERACTION INHIBITORS)	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

In regard to the above identified application, we are transmitting herewith the attached:


1. Information Disclosure Statement,
2. PTO Form-1449 (2 pages),
3. Copies of twenty-three (23) references, and
4. Return postcard.


With respect to additional fees, no additional fee is required. The Commissioner is nevertheless authorized to charge any additional fees or credit overpayment to Deposit Account No. 19-0733.

Respectfully submitted,

Date:

October 27, 2004


John P. Iwanicki, Reg. No. 34,628
BANNER & WITCOFF, LTD.
28 State Street, 28th Floor
Boston, MA 02109
Telephone: (617) 720-9600



PATENT
ATTORNEY DOCKET NO. 10498-00059

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Donald M. Coen and Beatrice D. Pilger

Serial No.: 10/712,785

Filed: November 13, 2003

Title: METHOD FOR DETERMINING PROTEIN
INTERACTION INHIBITORS

Examiner:

Art Unit: 2812

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.97-1.99, Applicants hereby submit the enclosed PTO Form 1449. A copy of the United States patent cited herein is not being submitted according to the August 5, 2003, U.S. Patent and Trademark Office Official Gazette Notice regarding Information Disclosure Statement filings. Copies of the remaining references are enclosed. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. § 1.56 and is being filed before the mailing date of a first office Action on the merits. Accordingly, no fee is due.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no

USSN 10/712,785
Express Mail Receipt No. EV 396915023 US


representation is intended as to the relative importance of any portion of the references. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. § 102 or § 103.

Please apply any charges or credits to Deposit Account No. 19-0733.

Respectfully submitted,

Date:

October 27, 2004



John P. Iwanicki, Reg. No. 34,628
BANNER & WITCOFF, LTD.
28 State Street, 28th Floor
Boston, MA 02109
Telephone: (617) 720-9600

USPTO Form 1449 U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 10498-00059		Serial No. 10/712,785		
INFORMATION DISCLOSURE CITATION Sheet 1 of 2				Applicants: Donald M. Coen and Beatrice D. Pilger		
Filing Date: November 13, 2003				Group: 2812		
U.S. PATENT DOCUMENTS						
Examiner Initial	Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
AA	5,223,391	06/29/93	Coen et al.	435	5	02/21/90
FOREIGN PATENT DOCUMENTS						
Examiner Initial	Document No.	Date	Country	Class	Subclass	Translation
						YES NO
AB	WO 00/68185	11/16/00	PCT			
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)						
	AC	Bridges et al., "Secondary structure and structure-activity relationships of peptides corresponding to the subunit interface of herpes simplex virus DNA polymerase," <i>J. Biol. Chem.</i> , 275(1):472-478 (2000)				
	AD	Bridges et al., "Identification of crucial hydrogen-bonding residues for the interaction of herpes simplex virus DNA polymerase subunits via peptide display, mutational, and calorimetric approaches," <i>J. Virol.</i> , 75(11):4990-4998 (2001)				
	AE	Chow and Coen, "Mutations that specifically impair the DNA binding activity of the herpes simplex virus protein UL42," <i>J. Virol.</i> , 69(11):6965-6971 (1995)				
	AF	Coen et al., "Sensitivity of arabinosyladenine-resistant mutants of herpes simplex virus to other antiviral drugs and mapping of drug hypersensitivity mutations to the DNA polymerase locus," <i>J. Virol.</i> , 53(2):477-488 (1985)				
	AG	Degtarev et al., "Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL," <i>Natl. Cell Biol.</i> , 3(2):173-182 (2001)				
	AH	Digard and Coen "A novel functional domain of an alpha-like DNA polymerase. The binding site on the herpes simplex virus polymerase for the viral UL42 protein," <i>J. Biol. Chem.</i> , 265(29):17393-17396 (1990)				
	AI	Digard et al., "Functional analysis of herpes simplex virus UL42 protein," <i>J. Virol.</i> , 67:1159-1168 (1993)				
	AJ	Digard et al., "The extreme C terminus of herpes simplex virus DNA polymerase is crucial for functional interaction with processivity factor UL42 and for viral replication," <i>J. Virol.</i> , 67(1):398-406 (1993)				
	AK	Digard et al., "Specific inhibition of herpes simplex virus DNA polymerase by helical peptides corresponding to the subunit interface," <i>Proc. National. Acad. Sci. USA.</i> , 92:1456-1460 (1995)				
	AL	Digard et al., "Mutational analysis of DNA polymerase substrate recognition and subunit interactions using herpes simplex virus as prototype," <i>Methods Enzymol.</i> , 262:303-322 (1995)				
	AM	Gottlieb et al., "The Herpes Simplex Virus Type 1 UL42 Gene Product; a Subunit of DNA Polymerase that Functions to Increase Processivity," <i>J. Virol.</i> , 64(12):5976-5987 (1990)				
EXAMINER				DATE CONSIDERED		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. **Copies of references not provided at the time of this submission.						

INFORMATION DISCLOSURE CITATION

Sheet 2 of 2

Applicants: **Donald M. Coen and Beatrice D. Pilger**Filing Date: **November 13, 2003**Group: **2812**

OCT 27 2004

U.S. PATENT DOCUMENTS

Examiner Initial	Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
BA						

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document No.	Date	Country	Class	Subclass	Translation	
						YES	NO
BB							

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

BC	Gottlieb and Challberg, "Interaction of herpes simplex virus type 1 DNA polymerase and the UL42 accessory protein with a model primer template," <i>J. Virol.</i> , 68(8):4937-4945 (1994)
BD	Hamatake et al., "The herpes simplex virus type 1 DNA polymerase accessory protein, UL42, contains a functional protease-resistant domain," <i>J. Gen. Virol.</i> , 74 (Pt 10):2181-2189 (1993)
BE	Loregian et al., "Intranuclear delivery of an antiviral peptide mediated by the B subunit of <i>Escherichia coli</i> heat-labile enterotoxin," <i>Proc. Natl. Acad. Sci. USA.</i> , 96:5221-5226 (1999)
BF	Marsden et al., "Role of the carboxy terminus of herpes simplex virus type 1 DNA polymerase in its interaction with UL42," <i>J. Gen. Virol.</i> , 75:3127-3135 (1994)
BG	Pritchard and Stefano, "Amplified detection of viral nucleic acid at subattomole levels using Q beta replicase," <i>Ann. Biol. Clin.</i> , (Paris) 48(7):492-497 (1990)
BH	Stow et al., "Inhibition of herpes simplex virus type 1 DNA replication by mutant forms of the origin-binding protein," <i>Virology</i> , 196:413-418 (1993)
BI	Tenney et al., "Deletions of the carboxy terminus of herpes simplex virus type 1 UL42 define a conserved amino-terminal functional domain," <i>J. Virol.</i> , 67(4):1959-1966 (1993)
BJ	Tenney et al., "Mutations in the C terminus of herpes simplex virus type 1 DNA polymerase can affect bonding and stimulation by its accessory protein UL42 without affecting basal polymerase activity," <i>J. Virol.</i> , 67(1):543-547 (1993)
BK	Weisshart et al., "Structural and functional organization of herpes simplex virus DNA polymerase investigated by limited proteolysis," <i>J. Biol. Chem.</i> , 269(36):22788-22796 (1994)
BL	Weisshart et al., "Herpes simplex virus processivity factor UL42 imparts increased DNA-binding specificity to the viral DNA polymerase and decreased dissociation from primer-template without reducing the elongation rate." <i>J. Virol.</i> , 73(1):55-66 (1999)
BM	Zuccola et al., "The crystal structure of an unusual processivity factor, herpes simplex virus UL42, bound to the C terminus of its cognate polymerase," <i>Mol. Cell.</i> , 5:267-278 (2000)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. **Copies of references not provided at the time of this submission.